CA: A Cancer Journal for Clinicians, Vol 26, 351-359, Copyright
© 1976 by American Cancer Society
Osteogenic Sarcoma: Advances in Treatment
Norman Jaffe M.D.1 and
Emil Frei III M.D.2
1 Chief, Pediatrics Solid Tumor Service, Sidney Farber Cancer Institute, and Senior Associate, Children's Hospital Medical Center and Associate Professor, Harvard Medical School, Boston, Massachusetts.
2 Director and Physician in Chief, Sidney Farber Cancer Institute, and Professor of Medicine, Harvard Medical School, Boston.
While major progress has been achieved in the treatment of all stages of osteogenic sarcoma, the results must be interpreted in the framework of a maximum follow-up of four years.
Attempts to confirm and extend these studies and results are under way. Several problems remain, such as long-term functional capacity of the preserved limb and late relapses. Future prospects include further improvements in chemotherapeutic regimens, the development of immunotherapy and the possibility of controlling the primary tumor by radiotherapy rather than surgery after cytoreduction with chemotherapy.
